Synopsis Autosomal dominant polycystic kidney disease (ADPKD) is prevalent in one out of 1000 patients. ADPKD is characterized by slow progressive renal cyst growth, arterial hypertension, and recurrent urinary tract infections. Clinical treatment of ADPKD is a lengthy procedure and the development of an effective preventive treatment is difficult. The patients have a well-controlled renal function despite the growth of cysts and the loss of normal tissues.
The present article reveals a summary of a 2-year follow-up study that examined the efficacy of everolimus in preventing end-stage renal disease in patients with ADPKD. This ‘Journal Watch’ discusses the study “Everolimus in patients with Autosomal Dominant Polycystic Kidney Disease” from the New England Journal Of Medicine . Authors: Gerd Walz, Klemens Budde, Marwan Mannaa, et al What was the need for the study? In the treatment of…
